Orchestra BioMed Enrolls First Patient in Sirolumus AngioInfusion Balloon Trial
Orchestra BioMed (Nasdaq:OBIO) announced the first patient enrollments in a study of its Virtue Sirolimus AngioInfusion Balloon (SAB).
The FDA investigational device exemption (IDE) trial compares the Virtue SAB to the Boston Scientific Agent paclitaxel-coated balloon, currently the only FDA-approved drug-coated balloon (DCB) for coronary indication.
- The trial is expected to enroll up to 740 patients across up to 75 centers in the U.S.
- Initial cases took place at The Christ Hospital Heart & Vascular Institute in Cincinnati, Ohio, and St. Francis Hospital & Heart Center in Roslyn, New York.
Orchestra BioMed won FDA IDE in April and continues to advance its atrioventricular interval modulation (AVIM) therapy.
Author's summary: Orchestra BioMed starts trial for Virtue Sirolimus AngioInfusion Balloon.
More News
- Pastors and professionals
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- UK businesses more likely to rely on brokers for risk management than global peers - Insurance Age
- Novartis to Acquire Avidity Biosciences for US$12 Billion in Rare-Disease Push
- Two killed as gunfire erupts during funeral for airstrike victims in Chin State
- Elon Musk’s Unveils Grokipedia - IT News Africa | Business Technology, Telecoms and Startup News
- LGBTQ+ community center announces new programming
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- Fraternity and hope strengthen relations between Catholics and Anglicans
- We need more faith spaces that affirm the LGBTQ communities – Baptist News Global